Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Autolus Therapeutics (AUTL) Net Margin (2017 - 2025)

Historic Net Margin for Autolus Therapeutics (AUTL) over the last 9 years, with Q3 2025 value amounting to 373.3%.

  • Autolus Therapeutics' Net Margin changed N/A to 373.3% in Q3 2025 from the same period last year, while for Sep 2025 it was 439.68%, marking a year-over-year increase of 22358300.0%. This contributed to the annual value of 2180.45% for FY2024, which is 100918100.0% up from last year.
  • As of Q3 2025, Autolus Therapeutics' Net Margin stood at 373.3%.
  • Autolus Therapeutics' Net Margin's 5-year high stood at 229.02% during Q2 2025, with a 5-year trough of 95193.1% in Q4 2024.
  • Moreover, its 5-year median value for Net Margin was 2443.31% (2023), whereas its average is 13592.59%.
  • As far as peak fluctuations go, Autolus Therapeutics' Net Margin plummeted by -99599600bps in 2022, and later soared by 192451600bps in 2023.
  • Quarter analysis of 5 years shows Autolus Therapeutics' Net Margin stood at 14402.97% in 2021, then surged by 95bps to 737.33% in 2022, then plummeted by -1432bps to 11292.86% in 2023, then tumbled by -743bps to 95193.1% in 2024, then skyrocketed by 100bps to 373.3% in 2025.
  • Its Net Margin was 373.3% in Q3 2025, compared to 229.02% in Q2 2025 and 781.13% in Q1 2025.